More recently developed ampakine compounds are much more potent and selective for the AMPA receptor target, and while none of the newer selective ampakine compounds have yet come onto the market, various ampakines are in clinical trials.[1]
A wide range of ampakines have been developed byRespireRx, which hold patents covering most medical uses of this class of drugs. The best known compounds that have come out of the RespireRx drug development program areCX-516 (Ampalex),CX-546,CX-614,CX-691 (farampator), andCX-717.ORG-26576 was developed by RespireRx but then licensed to Organon for development.
Several other compounds such asCX-701,CX-1739,CX-1763 andCX-1837 have also been announced as being under current investigation, and while little information has yet been released about them, CX-1739 is believed to be the most potent compound in this class to date, reportedly some 5x the potency ofCX-717.
Presently, CX717 is in phase II clinical trials as a possible non-stimulant pharmacotherapy in the treatment ofADHD.[3] As the AMPA receptors also mediate respiratory drive, CX717 is also being investigated as a therapy in opioid-induced respiratory depression andspinal-cord injury.
Few side effects have been determined, but an ampakine calledfarampator (CX-691) has side effects including headache, drowsiness, nausea, and impairedepisodic memory.[4]
^abcdeFroestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors".Journal of Alzheimer's Disease.32 (4):793–887.doi:10.3233/JAD-2012-121186.PMID22886028.
^O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES (June 2004). "AMPA receptor potentiators for the treatment of CNS disorders".Current Drug Targets. CNS and Neurological Disorders.3 (3):181–194.doi:10.2174/1568007043337508.PMID15180479.
Arai A, Lynch G (December 1992). "Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation".Brain Research.598 (1–2):173–184.doi:10.1016/0006-8993(92)90181-8.PMID1486479.S2CID9775469.
Arai A, Silberg J, Kessler M, Lynch G (June 1995). "Effect of thiocyanate on AMPA receptor mediated responses in excised patches and hippocampal slices".Neuroscience.66 (4):815–827.doi:10.1016/0306-4522(94)00616-D.PMID7544449.S2CID41021252.
Suppiramaniam V, Bahr BA, Sinnarajah S, Owens K, Rogers G, Yilma S, et al. (May 2001). "Member of the Ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptors".Synapse.40 (2):154–158.doi:10.1002/syn.1037.PMID11252027.S2CID9705232.
